Skip to main content

Branded

  • FDA declines to approve Takeda diabetes drug

    DEERFIELD, Ill. — The Food and Drug Administration declined to approve a drug made by Takeda Pharmaceutical, the drug maker said.

    Takeda announced that the FDA issued a complete response letter for its regulatory applications for the Type 2 diabetes drug alogliptin and a combination pill that includes alogliptin and pioglitazone, the active ingredient in the drug Actos.

  • Reports: GSK calls $2.6 billion offer for Human Genome Sciences 'full and fair'

    NEW YORK — GlaxoSmithKline said its offer to buy Human Genome Sciences was "full and fair" Wednesday after HGS turned it down last week, according to published reports.

    Reuters reported that GSK's $13-per-share, $2.6 billion offer for HGS would give the former full control of Benlysta (belimumab), the first new drug approved by the Food and Drug Administration for lupus in more than half a century. The two companies developed the drug together under a partnership, and the drug received approval in March 2011.

  • Amgen to buy Turkish drug maker for $700 million

    THOUSAND OAKS, Calif. — Biotech drug maker Amgen is buying a pharmaceutical company based in Turkey, the companies said Wednesday.

    Amgen said it would acquire 95.6% of Istanbul-based Mustafa Nevzat for $700 million in an all-cash deal, saying the purchase would allow it to expand in Turkey and the surrounding region. The company, also known as MN, is a major supplier of injectable drugs in Turkey and, increasingly, an exporter of medicines.

  • Amgen's founding CEO passes away

    THOUSAND OAKS, Calif. — George Rathmann, Amgen's founding CEO, has passed away, the drug maker announced Monday.

  • FDA outlines global food, drug, device safety strategy

    SILVER SPRING, Md. — Globalization has led to a rapid increase in the drugs and foods arriving on U.S. shores from abroad, a trend that has prompted U.S. regulators to transform their approach.

    The Food and Drug Administration released a report Monday detailing its strategies for what it called transforming from a domestic to a global public health agency.

  • Watson launches authorized generic diabetes drug

    PARSIPPANY, N.J. — Watson Pharmaceuticals announced the launch of an authorized generic version of a drug used to lower blood glucose in patients with Type 2 diabetes.

  • AstraZeneca buys Ardea Biosciences for $1.26 billion

    SAN DIEGO — Anglo-Swedish drug maker AstraZeneca will buy a San Diego-based biotech company for $1.26 billion, the two said Monday.

  • Anda facilitates commerce

    PALM BEACH, Fla. — More than 250 executives joined Anda for its 5th Annual Supply Chain Symposium here Thursday and Friday.

    (For photos of the event, click here.)

X
This ad will auto-close in 10 seconds